Compounded Semaglutide

A single GLP-1 receptor agonist that mimics the action of incretin hormones.

It slows stomach emptying, which can help you feel full for longer.

It also helps your liver regulate sugar production and reduces cravings.

Compounded Tirzepatide

A dual agonist that targets both the GLP-1 and glucagon receptors.

It stimulates the body's production of GLP-1 and GIP hormones.

The dual action may make it more effective at supporting metabolic health.

Both compounded medications can help manage food intake and support glycemic control.

Patients may notice changes within several weeks of beginning treatment.

Most common side effects are nausea, vomiting, stomach upset, diarrhea, tiredness, dizziness, or constipation. Initial side effects usually lessen as you continue treatment.

Individual responses vary. Maintaining consistent treatment and healthy habits may support your wellness goals. Tracking progress can be helpful during your journey.

Compounded Semaglutide may be appropriate for individuals with a BMI of 30+, or 27+ with weight-related health considerations like hypertension or insulin resistance.

Some patients may notice changes after dose adjustments, often within several weeks.

They are injected subcutaneously, typically in the abdomen, under medical guidance.

Not recommended for:

• Pregnant/breastfeeding women

• Those with pancreatitis history

• Type-1 diabetics

• Those with medication allergies

• Individuals with Multiple Endocrine Neoplasia syndrome type 2

Consult our medical team to determine if these options align with your health needs.